People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.
Healthcare systems worldwide are addressing polypharmacy as a major public health issue, with new guidance emphasizing person-centered medication reviews and risk mitigation strategies across multiple clinical settings including infectious disease care.
Researchers at Adelaide University found that salcaprozate sodium (SNAC), used in oral semaglutide formulations, was associated with gut bacteria changes, elevated inflammatory markers, and reduced brain-derived protein levels in a 21-day animal study.
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07605130 |
Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial |
NOT_YET_RECRUITING | PHASE4 |
| NCT07585500 |
Virtual Reality for Recovery After Intensive Care (PICS) |
RECRUITING | NA |
| NCT07581639 |
Comparison of Live and Virtual Music-based Interventions in Mitigating Stress |
COMPLETED | NA |
| NCT07578896 |
Maze Balance Board Training Effects on Mobility and Motor Skills in Cognitively Impaired Children |
RECRUITING | NA |
| NCT07570719 |
Community-based Screening for Alzheimer's Disease |
RECRUITING | |
| NCT07560696 |
Feasibility of Web-based Therapy Sessions |
RECRUITING | NA |
| NCT07547319 |
Effects of Accelerated rTMS on Cognitive Function |
NOT_YET_RECRUITING | NA |
| NCT07523113 |
ME/CFS Brain Fog: Cognitive Rehabilitation Trial |
NOT_YET_RECRUITING | NA |
| NCT07512739 |
A Sitting Tai Chi Programme for Chronic Stroke Survivors With Post-stroke Cognitive Impairment |
RECRUITING | NA |
| NCT07508215 |
Efficacy of Spectrally Optimized Light on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms |
NOT_YET_RECRUITING | NA |
